GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuvation Bio Inc (NYSE:NUVB) » Definitions » Total Long-Term Assets

Nuvation Bio (Nuvation Bio) Total Long-Term Assets : $1.18 Mil (As of Sep. 2021)


View and export this data going back to 2020. Start your Free Trial

What is Nuvation Bio Total Long-Term Assets?

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Nuvation Bio's Total Long-Term Assets for the quarter that ended in Sep. 2021 was $1.18 Mil.


Nuvation Bio Total Long-Term Assets Historical Data

The historical data trend for Nuvation Bio's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nuvation Bio Total Long-Term Assets Chart

Nuvation Bio Annual Data
Trend Dec20 Dec21
Total Long-Term Assets
143.76 4.08

Nuvation Bio Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
Total Long-Term Assets Get a 7-Day Free Trial 143.76 1.19 1.19 1.18 4.08

Nuvation Bio Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.


Nuvation Bio Total Long-Term Assets Related Terms

Thank you for viewing the detailed overview of Nuvation Bio's Total Long-Term Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Nuvation Bio (Nuvation Bio) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
1500 Broadway, Suite 1401, New York, NY, USA, 10036
Nuvation Bio Inc is a biopharmaceutical company. The company is engaged in developing therapeutic candidates for the unmet needs in oncology. The firm operates in pharmaceutical, biotechnology and other related markets that develop small molecules and drug conjugates as treatments for cancer patients.